Format

Send to

Choose Destination
Eur J Immunol. 2019 May;49(5):790-800. doi: 10.1002/eji.201847955. Epub 2019 Mar 7.

Interferon signature in patients with STAT1 gain-of-function mutation is epigenetically determined.

Author information

1
Department of Biomedicine, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
2
Department of Paediatric Immunology and Infectious Diseases, Our Lady's Children's Hospital, Crumlin, Dublin, Ireland.
3
Immunobiology of Dendritic Cells Unit, Inserm U1223, Institut Pasteur, Paris, France.
4
Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
5
Department of Biomedicine, Aarhus University, Aarhus, Denmark.
6
Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
7
Department of emergency care and acute infections, Tallinn Children's Hospital, Tallinn, Estonia.
8
Great Ormond Street Hospital & UCL Great Ormond Street Institute of Child Health, London, United Kingdom.
9
Otto Warburg Laboratory, Max Planck Institute for Molecular Genetics, Berlin, Germany.
10
Laboratory of Functional Genomics, Nutrigenomics and Systems Biology, Max-Delbrück-Center for Molecular Medicine (BIMSB/BIH), Berlin, Germany.
11
Department of Medical Sciences, Molecular Medicine and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
12
Estonian Genome Center, University of Tartu, Tartu, Estonia.

Abstract

STAT1 gain-of-function (GOF) variants lead to defective Th17 cell development and chronic mucocutaneous candidiasis (CMC), but frequently also to autoimmunity. Stimulation of cells with STAT1 inducing cytokines like interferons (IFN) result in hyperphosphorylation and delayed dephosphorylation of GOF STAT1. However, the mechanism how the delayed dephosphorylation exactly causes the increased expression of STAT1-dependent genes, and how the intracellular signal transduction from cytokine receptors is affected, remains unknown. In this study we show that the circulating levels of IFN-α were not persistently elevated in STAT1 GOF patients. Nevertheless, the expression of interferon signature genes was evident even in the patient with low or undetectable serum IFN-α levels. Chromatin immunoprecipitation (ChIP) experiments revealed that the active chromatin mark trimethylation of lysine 4 of histone 3 (H3K4me3), was significantly enriched in areas associated with interferon-stimulated genes in STAT1 GOF cells in comparison to cells from healthy donors. This suggests that the chromatin binding of GOF STAT1 variant promotes epigenetic changes compatible with higher gene expression and elevated reactivity to type I interferons, and possibly predisposes for interferon-related autoimmunity. The results also suggest that epigenetic rewiring may be responsible for treatment failure of Janus kinase 1/2 (JAK1/2) inhibitors in certain patients.

KEYWORDS:

STAT1 gain-of-function mutation; autoimmunity; chronic mucocutaneous candidiasis; epigenetics; type I interferon

PMID:
30801692
DOI:
10.1002/eji.201847955

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center